DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. (25th March 2021)

• Record Type: Journal Article
• Authors: Ferraro, Gino; Ali, Ahmed; Luengo, Alba; Kodack, David; Deik, Amy; Abbott, Keene; Bezwada, Divya; Blanc, Landry; Prideaux, Brendan; Jin, Xin; Possada, Jessica; Chen, Jiang; Chin, Christopher; Amoozgar, Zohreh; Ferreira, Raphael; Chen, Ivy; Naxerova, Kamila; Ng, Christopher; Westermark, Anna; Duquette, Mark; Roberge, Sylvie; Lyssiotis, Costas; Duda, Dan; Golub, Todd; Cantley, Lewis; Asara, John; Davidson, Shawn; Fukumura, Dai; Dartois, Véronique; Clish, Clary; Heiden, Matthew Vander; Jain, Rakesh;
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 1
• Page Start: i7
• Page End: i8
• Publication Date: 2021-03-25
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab024.029
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Brain metastases are refractory to therapies that otherwise control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the unique brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore metabolic adaptations required for breast cancer growth in the brain microenvironment may also introduce liabilities that can be exploited for therapy. Here, we assessed how metabolism differs between breast tumors growing in the brain versus extracranial sites and found that fatty acid synthesis is elevated in breast tumors growing in the brain. We determine that this phenotype is an adaptation to decreased lipid availability in the brain relative to other tissues, which results in a site-specific dependency on fatty acid synthesis for breast tumors growing at this site. Genetic or pharmacological inhibition of fatty acid synthase (FASN) reduces HER2+ breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies.